Analysis of Nuclear Dna and Morphometry, and Proliferating Cell Nuclear Antigen in Primary and Metastatic Malignant Melanoma

References

• Armitage P. Statistical methods in medical research. Oxford Blackwell Scientific Publications. 1971; 189–268
   Google Scholar
• Auer G U, Caspersson T O, Wallgren A. DNA content and survival in mammary carcinoma. Anal Quant Cytol 1980; 2: 161–165
   PubMedGoogle Scholar
• Auer G U, Arrhenius E, Granberg P O, Fox C H. Comparison of DNA distributions in primary human breast cancers and their metastases. Eur J Cancer 1980; 16: 273–278
   Web of Science ®Google Scholar
• Baak J PA, Tan G. The adjuvant prognostic value of nuclear morphometry in stage I malignant melanoma of the skin. A multivarate analysis. Anal Quant Cytol Histol 1986; 8: 241–244
   PubMedGoogle Scholar
• Balaban G, Herlyn M, Clark W H, Nowell P C. Karyotypic evolution in human malignant melanoma. Cancer Genet Cytogenet 1986; 19: 113–122
   PubMed Web of Science ®Google Scholar
• Björnhagen V, Månsson-Brahme E, Lindholm J, Mattsson A, Auer G. Morphometric, DNA and PCNA analyses in thin malignant melanomas. Med Oncol Tumor Pharmacother 1993; 10: 87–94
   PubMedGoogle Scholar
• Bravo R, Frank R, Blundell P A, Macdonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature 1987; 326: 515–517
   PubMed Web of Science ®Google Scholar
• Bröcker E.-B., Suter L, Brüggen J, Ruiter D J, Macher E, Sorg C. Phenotypic dynamics of tumor progression in human malignant melanoma. Int J Cancer 1985; 36: 29–35
   PubMed Web of Science ®Google Scholar
• Bäckdahl M, Auer G, Forsslund G, et al. Prognostic value of nuclear DNA-content in follicular thyroid tumors. Acta Chir Scand 1986; 152: 1–7
   PubMedGoogle Scholar
• Bäckdahl M, Cohn K, Auer G, et al. Comparison of nuclear DNA content in primary and metastatic papillary thyroid carcinoma. Cancer Res 1985; 45: 2890–2894
   PubMed Web of Science ®Google Scholar
• Cho K R, Vogelstein B. Suppressor gene alterations in the colorectal adenomacarcinoma sequence. J Cell Biochem Suppl 1992; 16G: 137–141
   PubMedGoogle Scholar
• Cillo C, Mach J-P, Schreyer M, Carrel S. Antigenic heterogeneity of clones and subclones from human melanoma cell lines demonstrated by a panel of monoclonal antibodies and flow microfluorometry analysis. Int J Cancer 1984; 34: 11–20
   PubMedGoogle Scholar
• Coit D G, Rogatko A, Brennan M F. Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. Ann Surg 1991; 214: 627–636
   PubMed Web of Science ®Google Scholar
• Costa A, Silvestrini R, Grignolio E, Clemente C, Attili A, Testori A. Cell kinetics as a prognostic tool in patients with metastatic malignant melanoma of the skin. Cancer 1987; 60: 2797–2800
   PubMedGoogle Scholar
• Cox D R. Regression models and life-tables (with discussion). Journal of the Royal Statistical Society 1972; 34: 187–220
   Google Scholar
• Diebold J, Lai M D, Liohrs U. Analysis of proliferative activity in colorectal mucosa by immunohistochemical detection of proliferating cell nuclear antigen (PCNA). Methodological aspects and application to routine diagnostic material. Virchows Arch B Cell Pathol 1992; 62: 283–289
   Google Scholar
• Forsslund G, Esposti P, Nilsson B, Zetterberg A. The prognostic significance of nuclear DNA content in prostatic carcinoma. Cancer 1992; 69: 1432–1439
   PubMed Web of Science ®Google Scholar
• Gamel J W, McLean I W. Computerized histopathologic assessment of malignant potential. A practical method for predicting survival following enucleation for uveal melanoma. Cancer 1983; 5: 1032–1038
   Google Scholar
• Garcia R L, Coltrera M D, Gown A M. Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis. Am J Pathol 1989; 134: 733–739
   PubMed Web of Science ®Google Scholar
• Hall P A, Levison D A, Woods A L, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990; 162: 285–294
   PubMed Web of Science ®Google Scholar
• Helander K G, Tribukait B. Modal DNA values of normal and malignant urothelial cells of the bladder in relation to nuclear size. Anal Quant Cytol Histol 1988; 10: 127–133
   PubMedGoogle Scholar
• Heppner H G. Tumor heterogeneity. Cancer Res 1984; 44: 2259–2265
   PubMed Web of Science ®Google Scholar
• Herlyn M, Balaban G, Bennicelli J, et al. Primary melanoma cells from the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst 1985; 74: 283–289
   PubMedGoogle Scholar
• Kamel O W, LeBrun D P, Davis R E, Berry G J, Warnke R A. Growth fraction estimation of malignant lymphomas in formalin-fixed paraffin-embedded tissue using anti-PCNA/cyclin 19A2. Correlation with Ki-67 labelling. Am J Pathol 1991; 138: 1471–1477
   PubMed Web of Science ®Google Scholar
• Kamino H, Ratech H. Improved detection of aneuploidy in malignant melanoma using multiparameter flow cytometry for S-100 protein and DNA content. J Invest Dermatol 1989; 93: 392–396
   PubMedGoogle Scholar
• Karlsson M, Boeryd B, Carstensen J, Kågedal B, Bratel Ternesten A., Wingren S. DNA ploidy and S-phase in primary malignant melanoma as prognostic factors for stage III disease. Br J Cancer 1993; 67: 134–138
   PubMedGoogle Scholar
• Kheir S M, Bines S D, von Roenn J H, Soong S-J, Urist M M, Coon J S. Prognostic significance of DNA aneuploidy in stage I cutaneous melanoma. Ann Surg 1988; 207: 455–461
   PubMed Web of Science ®Google Scholar
• Kreicbergs A, Zetterberg A. Cytophotometric DNA measurements of chondrosarcoma. Methodological aspects of measurements in tissue sections from old paraffin-embedded specimens. Anal Quant Cytol 1980; 2: 84–92
   PubMedGoogle Scholar
• Limon J, Gibas Z, Babinska M, et al. Chromosome changes associated with spontaneous phenotypic variation of transplantable melanoma. Cancer Genet Cytogenet 1987; 25: 123–129
   PubMedGoogle Scholar
• Lindholm C, Hofer P Å., Jonsson H. Karyometric findings and prognosis of stage I cutaneous malignant melanomas. Acta Oncol 1988; 27: 227–234
   PubMed Web of Science ®Google Scholar
• Lindholm J, Rubio C A, Kato Y, Hata Y I. A morphometric method to discriminate normal from dysplastic/carcinoma in situ squamous epithelium in the human esophagus. Pathol Res Pract 1989; 184: 297–305
   PubMedGoogle Scholar
• Magno W B, Hirschfield L, Bhuiya T, Harrison G, Mir R. Correlation of proliferative index (PCNA reactivity and Ki-67 reactivity) in primary breast carcinoma with hormone status, lymph node status and disease-free survival. Conn Med 1992; 56: 667–669
   PubMedGoogle Scholar
• Moberger B. DNA content and prognosis in endometrial carcinoma. Medical dissertation, Karolinska Institute, Stockholm 1989
   Google Scholar
• Muhonen T, Pyrhönen S, Laasonen A, et al. Tumour growth rate and DNA flow cytometry parameters as prognostic factors in metastatic melanoma. Br J Cancer 1992; 66: 528–532
   PubMedGoogle Scholar
• Natali P G, Cavaliere R, Bigotti A, et al. Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. J Immunol 1983; 130: 1462–1466
   PubMedGoogle Scholar
• Nicolson G L, Rosenberg N. Diversification and progression of malignant tumors. Bioessays 1988; 6: 204–208
   Google Scholar
• Nomori H, Nakajima T, Noguchi M, Iga R, Shimosato Y. Cytofiuorometric analysis of metastases from lung adenocarcinoma with special reference to the difference between hematogenous and lymphatic metastases. Cancer 1991; 67: 2941–2947
   PubMedGoogle Scholar
• van den Ouden D, Tribukait B, Blom J HM, et al. The European organization for research and treatment of cancer genitourinary group. Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: Impact on time to progression. J Urol 1993; 150: 400–406
   PubMedGoogle Scholar
• Prelish G, Stillman B. Coordinated leading and legging strand synthesis during SV40 DNA replication in vitro requires PCNA. Cell 1988; 53: 117–126
   PubMedGoogle Scholar
• Rode J, Williams R A, Charlton I G, Dhillon A P, Moss E. Nuclear DNA profiles in primary melanomas and their metastases. Cancer 1991; 67: 2333–2336
   PubMedGoogle Scholar
• Stenkvist B, Bengtsson E, Eriksson O, Jarkrans T, Nordin B, Westman-Naeser S. Correlation between cytometric features and mitotic frequency in human breast carcinoma. Cytometry 1981; 1: 287–291
   PubMedGoogle Scholar
• Sørensen F B, Kristensen I B, Grymer F, Jakobsen A. DNA-index and stereological estimation of nuclear volume in primary and metastatic malignant melanomas: a comparative study with analysis of heterogeneity. APMIS 1990; 98: 61–70
   PubMed Web of Science ®Google Scholar
• Tan G, Baak J PA. Evaluation of prognostic characteristics of stage I cutaneous malignant melanoma. Anal Quant Cytol Histol 1984; 6: 147–154
   Google Scholar
• Tuccari G, Rizzo A, Muscarà M., Giuffré G., Barresi G. PCNA/cyclin expression in breast carcinomas: its relationships with Ki-67, ER, PgR immunostainings and clinicopathological aspects. Pathologica 1993; 85: 47–55
   PubMedGoogle Scholar
• Vogelstein B, Fearon E R, Hamilton S R, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 523–532
   Google Scholar
• Wass J, Zbroja R A, Young G AR, Vincent P C, Joyce R M, Croaker G. Malignant melanoma: analysis by flow cytometry. Pathology 1985; 17: 475–480
   PubMed Web of Science ®Google Scholar
• Williams R A, Charlton I G, Rode J. Comparative ploidy studies using cytological and paraffin section preparations. Cytopathology 1991; 2: 29–37
   PubMedGoogle Scholar
• Zeng S Q, Fu Y S, Cochran A J. Nuclear DNA measurement of metastatic melanoma by a computerized digital imaging system. Hum Pathol 1990; 21: 1112–1116
   PubMedGoogle Scholar